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Viruses exploit signaling pathways to their advantage during multiple stages of their life cycle. We demon-
strate a role for protein kinase A (PKA) in the hepatitis C virus (HCV) life cycle. The inhibition of PKA with
H89, cyclic AMP (cAMP) antagonists, or the protein kinase inhibitor peptide reduced HCV entry into Huh-7.5
hepatoma cells. Bioluminescence resonance energy transfer methodology allowed us to investigate the PKA
isoform specificity of the cAMP antagonists in Huh-7.5 cells, suggesting a role for PKA type II in HCV
internalization. Since viral entry is dependent on the host cell expression of CD81, scavenger receptor BI, and
claudin-1 (CLDN1), we studied the role of PKA in regulating viral receptor localization by confocal imaging
and fluorescence resonance energy transfer (FRET) analysis. Inhibiting PKA activity in Huh-7.5 cells induced
a reorganization of CLDN1 from the plasma membrane to an intracellular vesicular location(s) and disrupted
FRET between CLDN1 and CD81, demonstrating the importance of CLDN1 expression at the plasma mem-
brane for viral receptor activity. Inhibiting PKA activity in Huh-7.5 cells reduced the infectivity of extracellular
virus without modulating the level of cell-free HCV RNA, suggesting that particle secretion was not affected but
that specific infectivity was reduced. Viral particles released from H89-treated cells displayed the same range
of buoyant densities as did those from control cells, suggesting that viral protein association with lipoproteins
is not regulated by PKA. HCV infection of Huh-7.5 cells increased cAMP levels and phosphorylated PKA
substrates, supporting a model where infection activates PKA in a cAMP-dependent manner to promote virus
release and transmission.
Hepatitis C virus (HCV) is an enveloped positive-stranded
RNA virus and the sole member of the genus Hepacivirus
within the Flaviviridae. Approximately 170 million individuals
are infected with HCV worldwide, and the majority are at risk
for developing serious progressive liver disease. The HCV
RNA genome of approximately 9.6 kb encodes a polyprotein of
around 3,000 amino acids, which is cleaved by viral and cellular
proteases to generate the structural and nonstructural (NS)
proteins. The amino terminus of the polyprotein sequence
contains the structural proteins including the core, the enve-
lope glycoproteins (GPs) E1 and E2, and p7. The NS proteins
including NS2 through NS5 are located at the carboxy terminus
of the polyprotein. Much of our current understanding of HCV
replication has been gained through the use of genomic repli-
cons (reviewed in reference 7). The recent development of an
infectious system allowing the generation of HCV particles in
cell culture (HCVcc) has enabled the complete viral life cycle
to be explored (63, 99, 110).
Viruses utilize signaling pathways of their target cells to their
advantage during multiple steps of their life cycle including
entry, internalization, replication, and release (21, 24, 80, 87,
91). The lateral movement of human immunodeficiency virus
type 1 (HIV-1) and coxsackie B viruses along the membrane of
target cells prior to entry is dependent upon signaling pathways
that modulate the cytoskeleton to facilitate receptor attach-
ment and particle internalization (26, 59). Viral replication
exploits intracellular signaling pathways; for example, herpes
simplex virus expression is dependent on protein kinase A
(PKA) (103), HIV transcription and replication are increased
in response to the synergistic activation of PKA and protein
kinase C (PKC) (85), and vaccinia virus replication requires
the mitogen-activated protein kinase (MAPK) pathway (3).
Signaling molecules that play important roles in the secretory
pathway are utilized by viruses during particle assembly and
release (76).
Recent advances in methods to study HCV entry have dem-
onstrated the involvement of at least three host cell molecules:
the tetraspanin CD81 (82, 107), scavenger receptor class B
member I (SR-BI) (8, 41, 88), and the tight-junction (TJ)
protein claudin-1 (CLDN1) (34, 72, 104, 109). CD81 is a mem-
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ber of the tetraspanin family of expressed membrane proteins
that are reported to influence multiple cellular properties in-
cluding adhesion, morphology, and proliferation (reviewed in
reference 60). The intracellular domain of CD81 associates
with the signaling enzymes phosphatidylinositol 4-kinase and
PKC (9, 108). SR-BI expression within the liver is regulated by
cyclic AMP (cAMP)-dependent PKA phosphorylation of
PDZK1, and its transcytosis in polarized MDCK cells requires
PKA (18, 77). Many cellular signaling proteins are involved in
TJ formation, and the recently identified role of CLDN1 in
HCV entry highlights a route by which the virus could modu-
late target cell signaling to its advantage (6, 57, 62).
In this study, we investigated a role for protein kinase sig-
naling in HCV infection by examining the effect of kinase
inhibitors and antagonists on viral entry, replication, and the
release of infectious particles. Inhibition of PKA led to a re-
distribution of CLDN1 from the plasma membrane and a con-
comitant reduction in viral entry, confirming the importance of
CLDN1 localization at the plasma membrane for viral receptor
activity. In addition, we reveal a role for PKA in regulating the
infectivity of cell-free virus particles. Finally, we demonstrate
increased levels of cAMP and PKA substrates in HCV-infected
cells, supporting a model where infection activates PKA in a
cAMP-dependent manner as a mechanism to promote the
infectivity of extracellular virus and to aid viral transmission.
MATERIALS AND METHODS
Cell lines, antibodies, and reagents. Huh-7.5 cells (provided by Charles Rice,
The Rockefeller University, New York, NY) (14), Huh-7 cells (provided by
Frank Chisari, Scripps Research Institute), Hep3B, and 293T cells (purchased
from the American Type Culture Collection) were propagated in Dulbecco’s
modified Eagle medium (DMEM) supplemented with 10% fetal bovine serum
(FBS) and 1% nonessential amino acids (Invitrogen, CA). 293T cells transduced
to express CLDN1 (43) were propagated in 10% FBS–DMEM. Primary human
hepatocytes were isolated and cultured as previously reported (81). All cells were
grown in a humidified atmosphere at 37°C in 5% CO2.
The primary antibodies used were anti-CLDN1 JAY.8 (Invitrogen, CA), anti-
CLDN1 1C5-D9 (Novus, CO), anti-CD81 M38 (Fedor Berditchevski, University
of Birmingham, Birmingham, United Kingdom), anti-SR-BI 25 (BD Biosciences,
NJ), anti-NS5A 9E10 (C. Rice, Rockefeller University), and anti-phospho-Ser/
Thr PKA substrate (p-PKAs) (Cell Signaling Technology, Inc., MA). Secondary
labeled antibodies were obtained from Invitrogen: Alexa Fluor 488 goat anti-
mouse immunoglobulin G (IgG) Alexa Fluor 488 goat anti-rabbit IgG, and Alexa
Fluor 633 goat anti-mouse IgG. Horseradish peroxidase (HRP)-conjugated
sheep anti-mouse and donkey anti-rabbit secondary antibodies were obtained
from GE Healthcare.
Kinase inhibitor and antagonists were obtained from the following sources:
Ro-31-8220 and H89 from Calbiochem; Rp-cAMPS (adenosine 3",5"-cyclic phos-
phorothioate) and Rp-8-Br-cAMPS (Janet Lord, University of Birmingham,
Birmingham, United Kingdom) from BioLog; myristoylated protein kinase I
(14–22) amide (myrPKI) from Biomol International; and forskolin (FK), mito-
gen-activated protein kinase 1 (MEK1), PD98059, U0126, and SB203580 from
Sigma. Green fluorescent protein (GFP)–A-kinase-anchoring protein (AKAP) in
silico (AKAP-IS)–V5 (His), and GFP-Scrambled-V5 (His) were kindly donated
by John Scott (Howard Hughes Medical Center).
Genesis of virus and infections. Cell culture-derived virus particles, J6/JFH
and JFH-1, were generated as previously described (63). Briefly, using the
Megascript T7 kit (Ambion, Austin, TX), RNA was transcribed in vitro from
full-length genomes and electroporated into Huh-7.5 cells. High-titer stocks were
generated by serial passage through naı¨ve Huh-7.5 cells (34). Supernatants were
collected at 72 and 96 h postinfection, pooled, and stored at#80°C. Infected cells
were detected by methanol fixation and staining for NS5A using the anti-NS5A
9E10 antibody; bound antibody was detected with an Alexa 488-conjugated
anti-mouse IgG and quantified by flow cytometry.
Pseudoviruses expressing luciferase or enhanced GFP (eGFP) reporters were
generated by the following protocols. 293T cells were transfected with a 1:1 ratio
of plasmids encoding HIV provirus expressing luciferase and HCV strain H77
E1E2 envelope GPs (HCVpp-H77), MLV GP (MLVpp), or empty vector (Env-
pp), as previously described (49). Alternatively, 293T cells were cotransfected
with plasmids encoding HIV provirus expressing eGFP (CSGW) (11), HIV
Gag-Pol, and HCV strain JFH GPs or empty vector in a 1:1:4 ratio as previously
described (36). Supernatants were harvested 48 h posttransfection, pooled, and
filtered. Infection was quantified by measuring cellular eGFP expression by flow
cytometry or luciferase activity in a luminometer (Berthold Centro LB 960).
Specific infectivity was calculated by subtracting the mean Env-pp signal from the
HCVpp or MLVpp signal. Relative infectivity was calculated as a percentage of
untreated cells and presented as the standard error of the mean, where the mean
infection value of replicate untreated cell wells was defined as 100%.
Effect of kinase inhibitor/activators on HCV entry. Various target cells were
seeded at 1.5 $ 104 cells/cm2, subjected to a 3-h serum starvation the following
day, and incubated with inhibitors/agonists diluted in serum-free DMEM for 1 h.
HCVcc/HCVpp-containing medium was added to target cells and incubated for
1 h and 6 h, respectively, unbound virus/inhibitors were removed by washing, and
the medium was replaced with 3% FBS–DMEM. After 48 and 72 h for HCVcc
and HCVpp, respectively, infection was assessed as described above.
Effect of kinase inhibitor/activators on cell-free virus infectivity. To evaluate
the level of infectious virus released from J6/JFH- and JFH-1-infected cultures,
cells were seeded at 6 $ 104 cells/cm2 in 48-well plates, serum starved for 3 h the
following day, and incubated with modulators of PKA for 1 h. Cells were washed
extensively, and cell-free medium was collected for the quantification of infec-
tious virus or HCV RNA.
To quantify extracellular virus infectivity, the collected medium was allowed to
infect naı¨ve Huh-7.5 target cells at various dilutions for 1 h at 37°C. Intracellular
virus was released by three rapid freeze-thaw cycles of infected cells, and the
clarified lysate was used to infect Huh-7.5 cells. Viral infection was detected after
48 h by staining for NS5A, and antigen-positive cells were enumerated on a
Nikon TE2000 apparatus. Infectivity is defined as the number of infected cells or
units per ml (IU/ml) and expressed relative to control untreated cells as de-
scribed above.
BRET assay to investigate PKAI and PKAII dynamics in living cells. Biolu-
minescence resonance energy transfer (BRET) experiments were performed as
previously described (29, 83). In brief, 1.5 $ 104 Huh-7.5 cells were seeded per
well of a white 96-well microplate (Nunc, Thermo Fisher, Denmark) and trans-
fected with 0.2 %g of plasmids encoding PKA type I (PKAI) (GFP2-C3-hC&
[Perkin Elmer, Massachusetts] [83] and Renilla luciferase [Rluc]-N2-hRI&) and
PKAII (GFP2-C3-hC& and Rluc-N2-hRII&) sensors the following day. At 48 h
posttransfection, the cells were washed with phosphate-buffered saline (PBS)
and incubated with antagonists for 1 h. Subsequently, the cells were stimulated
with agonists in the presence of either 50 %M FK (Sigma, United Kingdom) and
500 %M 3-isobutyl-1-methylxanthine (IBMX; Sigma, United Kingdom) or FK
alone (10 %M) for 30 min in the continued presence of antagonists or were mock
treated with PBS (control). To quantify BRET, the medium was removed, 50 %l
of substrate (DeepBlueC in PBS) was added per well, and Rluc/GFP2 light
emission was detected using a Fusion&-FP microplate reader (Perkin-Elmer)
(84). The light output was measured consecutively (read time, 1 s; gain, 25) using
filters at a 410-nm wavelength ('80-nm bandpass) for the donor and at a 515-nm
wavelength ('30-nm bandpass) for the acceptor. The emission from nontrans-
fected (NT) cells was subtracted, and the BRET signal was calculated as follows:
[emission (515 nm)# NT cells (515 nm)]/[emission (410 nm)# NT cells (410 nm)].
Control measurements with cells expressing Rluc were included in each experiment
to determine the background BRET signal. Statistical analyses were performed with
GraphPad Prism, version 4 (GraphPad Software, San Diego, CA).
Imaging of CD81, CLDN1, SR-BI, and PKA substrate(s). Naı¨ve and JFH-1-
infected Huh-7.5 cells were seeded onto borosilicate glass coverslips at a density
of 1.5 $ 104 cells/cm2. The following day, cells were serum starved for 3 h,
incubated with H89 or FK for 1 h, and, dependent on the antibody to be used,
fixed in 1% paraformaldehyde (M38) or methanol (remaining antibodies). Cells
were permeabilized for 30 min in 0.1% saponin–1% bovine serum albumin
(BSA) in PBS and incubated with antibodies specific for CD81 (M38), SR-BI
(anti-ClaI), CLDN1 (1C5-D9), phospho-Ser/Thr PKA substrate (p-PKAs), or
NS5A (9E10). Cells were washed three times in PBS-saponin-BSA before the
addition of the relevant secondary Alexa Fluor-conjugated antibodies in PBS-
saponin-BSA for 1 h at room temperature. Cells were washed three times in
PBS-saponin-BSA before counterstaining with 4",6"-diamidino-2-phenylindole
(DAPI) (Invitrogen) in PBS for 5 min. Coverslips were mounted onto glass slides
(ProLong Gold antifade; Invitrogen, CA), and images were analyzed by laser
scanning confocal microscopy (Zeiss LSM510) with a 63$ water immersion
objective.
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FRET to quantify CLDN1-CD81 association. Huh-7.5 cells were transduced
with TRIP viruses encoding AcGFP.CD81 and DsRed.CLDN1 (43) and grown
on 22-mm-diameter borosilicate glass coverslips. Images were collected using a
Meta Head laser scanning confocal microscope (Zeiss, model LSM510), and
areas of protein colocalization (defined as 100% pixel overlap) were identified
using the colocalization finder plugin (42) and Image J software (W. S. Rasband,
U.S. National Institutes of Health, Bethesda, MD [http://rsb.info.nih.gov/ij/]).
Proteins within regions of interest were assessed for fluorescence resonance
energy transfer (FRET) as described previously (43). Briefly, the percentage of
fields where FRET occurs is an indicator of the frequency of protein-protein
associations. The efficiency of FRET was obtained by measuring the fluorescence
intensities of the donor fluorophore before and after photobleaching of the
acceptor fluorophore (10, 105). To minimize spectral bleedthrough, we utilized
the Meta Head function of the microscope at the following wavelengths: excita-
tion wavelength of 488 nm and emission wavelength of 520 nm for AcGFP and
excitation wavelength of 561 nm and emission wavelength of 600 nm for DsRed.
Statistical analyses were performed using Fisher’s exact test with correction for
multiple sampling where appropriate.
Immunoprecipitation and Western blotting. Huh-7.5 cells (seeded the preced-
ing day at 1.5 $ 104 cells/cm2) were harvested in lysis buffer (PBS, 1% Triton
X-100, 0.1% sodium deoxycholate, 0.1% sodium dodecyl sulfate [SDS]) contain-
ing protease (Complete; Roche, United Kingdom) and phosphatase (PhoStop;
Roche, United Kingdom) inhibitors. Cell lysates were clarified by centrifugation
(20,000 $ g for 30 min), and the protein concentration was determined using
protein assay reagent (Pierce, IL) according to the manufacturer’s instructions.
Quantified protein lysates (100 %g) were incubated for 4 h with 1 %g/ml anti-
CLDN1 (Jay.8) or phospho-Ser/Thr PKA substrate antibodies at 4°C. Protein
G-Sepharose beads (GE Healthcare, United Kingdom) were added, and follow-
ing a 1-h incubation at 4°C, beads were collected by centrifugation and washed
thoroughly in lysis buffer. Immunoprecipitated proteins were eluted from the
protein G-Sepharose beads using Laemmli buffer, separated by 12% SDS-poly-
acrylamide gel electrophoresis (PAGE), and transferred onto polyvinylidene
difluoride membranes (Sigma, United Kingdom) for incubation with anti-
CLDN1 (Jay.8) or phospho-Ser/Thr PKA substrate antibodies (1 %g/ml). Sec-
ondary antibodies, HRP-conjugated donkey anti-rabbit and sheep anti-mouse
IgG, were detected by enhanced chemiluminescence (Geneflow, United
Kingdom).
Quantification of HCV RNA. To measure the effect of H89 treatment on
intracellular and cell-free HCV RNA levels, RNA was extracted using the
RNeasy mini kit (Qiagen, Germany) and a QIAamp MinElute virus kit (Qiagen,
Germany), respectively, according to the manufacturer’s instructions. The am-
plification efficiencies of cell-free HCV RNA preparations were assessed by the
addition of a small quantity of exogenous HeLa RNA (10 pg) to the reverse
transcription (RT)-PCR mixture. HCV amplification was performed using a
modification of a method described previously by Cook and colleagues (25, 95)
in a single-tube RT-PCR in accordance with the manufacturer’s guidelines
(CellsDirect kit; Invitrogen, CA), and fluorescence was monitored using a 7900
HT real-time PCR machine (ABI, CA) (71). In all reaction mixtures, the house-
keeping gene glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was in-
cluded as an internal endogenous control for amplification efficiency and RNA
quantification (primer-limited endogenous control; ABI).
Quantification of extracellular albumin, ApoB, and ApoE. Huh-7.5 cells were
seeded at 6 $ 104 cells/cm2 in 48-well plates, subjected to a 3-h serum starvation
the following day, and incubated with inhibitors diluted in serum-free DMEM
for 1 h. Inhibitors were removed by washing, fresh 3% FBS–DMEM was added,
and after 1 h the cell-free medium was collected and tested for levels of albumin
(73), apolipoprotein B (ApoB), and apolipoprotein E (ApoE) using the follow-
ing enzyme-linked immunosorbent assay (ELISA) protocols. Briefly, Immulon
2HB ELISA plates (Thermo, MA) were coated with goat anti-human albumin
(Bethyl Laboratories, Montgomery, TX), and diluted samples or known stan-
dards were added for 1 h at room temperature. Bound albumin was detected with
an HRP-conjugated goat anti-human albumin (Bethyl Laboratories, TX). ApoB
and ApoE were measured using an in-house sandwich ELISA using rabbit
anti-human ApoB or ApoE capture antibodies (Dako, Denmark). After
blocking and washing, diluted samples or standards were added for 4 h at
37°C, and bound apolipoproteins were detected using HRP-conjugated rabbit
anti-human ApoB or ApoE antibodies. Bound HRP conjugates were detected
colorimetrically after reaction with a TMB substrate solution (BioFX, MD).
Quantification of HCV particle buoyant density. Linear iodixanol (Axis-
Shield, United Kingdom) gradients were prepared using a two-chamber gradient
maker (Jencons, United Kingdom) with light (6%) and dense (56%) iodixanol
solutions (78). Gradients were used immediately after preparation, and 0.4 ml of
virus was loaded onto each gradient. Samples were centrifuged at 100,000$ g for
21 h at 4°C in an L80-M ultracentrifuge (Beckman, United Kingdom). Fractions
were harvested by tube puncture, and the density was determined using a digital
refractometer (Atago, Japan). RNA was extracted from each fraction using a
Qiamp viral RNA kit (Qiagen, Germany) and quantified for HCV RNA.
Quantification of intracellular cAMP levels. Naı¨ve and HCV-infected cells (72
h postinfection) were seeded at 1.5 $ 104 cells/cm2, and cAMP levels were
determined as an index of adenylate cyclase activity, as previously described (48).
Cells were washed and incubated for 15 min at 37°C in medium containing 0.1%
BSA and 0.5 mM IBMX. Cells were incubated for 1 h in the presence and
absence of the cAMP agonist FK (10 %M), and reactions were terminated by
washing in ice-cold PBS. Cytoplasmic contents were extracted by scraping cells
into ice-cold 70% ethanol, and samples were stored on ice for 1 h. Supernatants
were separated from cell debris by centrifugation, and the pelleted material was
extracted with ethanol for 30 min and combined with the supernatants. Samples
were dried under a vacuum, and cAMP levels were measured using the
[3H]cAMP Biotrak assay kit according to the manufacturer’s instructions (GE
Healthcare, United Kingdom).
RESULTS
Protein kinases and HCV entry. To study the involvement of
protein kinases during HCVcc infection, we examined the ef-
fect of several inhibitors targeting PKC (Ro-31-8220), PKA
(H89), MEK1 (PD98059), MEK1/2 (U0126), and p38 MAPK
(SB203580) (20, 27, 33, 35, 56, 67). All inhibitors were used at
a concentration that was nontoxic for Huh-7.5 cells in a 3-(4,5-
dimethyl-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-
2H-tetrazolium assay (data not shown). Huh-7.5 cells were
treated for 1 h with the various inhibitors and infected with
JFH-1 for 1 h in the continued presence of the compounds.
Treatment of cells with the PKA inhibitor H89 reduced JFH-1
infectivity by 80%, whereas PKC or MAPK inhibitors had no
detectable effect (Fig. 1A). These results led us to study the
role of PKA in HCV infection in more detail.
cAMP-dependent kinase (PKA) exists as an inactive holoen-
zyme complex comprising two regulatory (R) and two catalytic
(C) subunits. Upon cAMP binding to the R subunits, the ho-
loenzyme dissociates and releases the C subunits, which phos-
phorylate substrate proteins in the cytosol and nucleus. H89
competes with ATP binding to the C subunit(s) and prevents
substrate phosphorylation (20). H89 treatment of Huh-7.5 cells
led to a dose-dependent inhibition of J6/JFH and JFH-1 in-
fectivity (Fig. 1B). However, H89 is reported to have off-target
effects (65). To verify a role for the catalytic subunit of PKA
(PKA-C) in HCV infection, we treated Huh-7.5 cells with a
myristoylated version of the naturally occurring protein kinase
inhibitor peptide (myrPKI) (44). myrPKI specifically inacti-
vates PKA activity by binding to the C subunits with subnano-
molar affinity (46, 54). The treatment of Huh-7.5 cells with
myrPKI inhibits J6/JFH and JFH-1 infectivity in a dose-depen-
dent manner (Fig. 1C), providing clear evidence for a role of
PKA-C in HCV infection.
To assess whether PKA has a specific role in HCV entry, we
studied the effect(s) of H89 and myrPKI on the ability of
Huh-7.5 cells to support HCVpp infection. H89 inhibited
HCVpp-JFH-1 infectivity in a dose-dependent manner and
had no effect on MLVpp infectivity (Fig. 2A), confirming a
specific inhibition of particles bearing HCVGPs. myrPKI dem-
onstrated a dose-dependent inhibition of HCVpp-H77 entry
and no detectable effect(s) on MLVpp infectivity (Fig. 2B),
further validating a role for PKA in HCV entry. To ascertain
whether the inhibitory effect of H89 was apparent in other cell
types, a range of cells were incubated with H89 as previously
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described. H89 inhibited HCVpp infection of all cell types
tested, including primary human hepatocytes (Fig. 2C), with no
discernible effect on MLVpp infectivity (data not shown).
Since HCVpp allow us to study GP-dependent entry indepen-
dent of downstream replication and translation events, we can
conclude that PKA has a role in HCV entry.
Inhibition of PKA can also be achieved by cAMP antago-
nists, which bind to the R subunit(s) and prevent holoenzyme
dissociation and activation. PKA exists as two isoforms defined
by their respective regulatory subunits, types I and II. Rp-8-
Br-cAMPS has been reported to preferentially inhibit PKAI
(30, 39, 66), whereas Rp-cAMPS inhibits both isoforms. To
discriminate a role for PKAI and PKAII, we studied the effect
of Rp-8-Br-cAMPS and Rp-cAMPS on the ability of Huh-7.5
cells to support HCV infection. Rp-cAMPS reduced J6/JFH
and JFH-1 infectivity, whereas Rp-8-Br-cAMPS had no effect
(Fig. 3A), suggesting a role for PKAII in HCV infection. To
ascertain whether the cAMP antagonists have differential effects
on PKAI and PKAII in Huh-7.5 cells, we used BRET to study the
PKA subunit interaction(s) with isoform-specific PKA sensors. R
and C subunits of PKA were tagged with Rluc as a biolumines-
cent donor or GFP as a fluorescent acceptor, respectively, allow-
ing the quantitative comparison of PKAI and PKAII regulation
(83). Following PKA activation, the holoenzyme dissociates, lead-
ing to a reduced BRET signal. FK activates PKA by stimulating
cAMP levels, causing the phosphorylation of substrates including
phosphodiesterases (PDEs), which degrade cAMP and thereby
reduce PKA activity.
To assess the antagonistic effect(s) of the Rp analogs on
PKAI and PKAII isoforms, we measured their ability to inhibit
FK/IBMX-induced holoenzyme dissociation. IBMX is a gen-
eral PDE inhibitor and is a prerequisite to observe effects on
the PKAI BRET sensor (83). In the presence of FK and
IBMX, Rp-8-Br-cAMPS and, to a lesser extent, Rp-cAMPS
could inhibit the type I BRET sensor but not the type II sensor
(Fig. 3B), suggesting specificity of Rp-8-Br-cAMPS for PKAI.
This effect is probably due to the differential distribution of
PKAI versus PKAII, where PKAII is clustered in subcellular
compartments via AKAPs to the plasma membrane and can be
stimulated by FK alone (96). Thus, the FK activation of PKA
in the presence of PDE inhibitors prolongs the time period of
PKA activity. In contrast, FK treatment failed to activate the
PKAI BRET sensor (Fig. 3C). However, PKAII dissociation
was promoted by endogenously elevated cAMP levels in re-
sponse to FK alone; this effect was reversed with Rp-cAMPS
but not Rp-8-Br-cAMPS, indicating PKA type II involvement
(Fig. 3C).
To investigate whether stimulating PKA activity enhances
HCV entry, Huh-7.5 cells were treated with FK for 1 h and
tested for their ability to support HCVcc and HCVpp infec-
tion. FK treatment increased J6/JFH and JFH-1 infectivity by
72% and 165%, respectively (Fig. 4A). This increase in infec-
tivity could be abrogated by prior treatment of cells with H89
(10 %M) (Fig. 4A), confirming the PKA dependency of the
effect. In contrast, FK treatment had no effect on HCVpp-
JFH-1 infectivity (Fig. 4B), suggesting that FK promotes HCV
infection postentry. No significant differences in the effect(s) of
FK treatment on HCV infection in the presence or absence
of IBMX were noted (data not shown).
Inhibition of PKA activity induces a reorganization of
CLDN1 in Huh-7.5 cells. HCV utilizes the cellular molecules
CD81, SR-BI, and CLDN1 to enter target cells. To investigate
whether the inhibitory activity of H89 involves these receptor
molecules, we studied their expression and localization in con-
trol or H89- or FK-treated cells. Flow cytometry demonstrated
that CD81, SR-BI, and CLDN1 expression levels were not
altered by H89 treatment (data not shown). H89 induced an
altered staining pattern of CLDN1, whereas CD81 localization
was unchanged (Fig. 5A). In untreated cells, CLDN1 localized
to the plasma membrane, predominantly at intercellular junc-
tions, whereas a fragmented pattern of plasma membrane
staining with intracellular CLDN1 was observed in H89-
treated cells (Fig. 5A). FK treatment had no detectable effect
on CLDN1 or CD81 localization. Rp-cAMPS induced a pat-
tern of CLDN1 localization similar to that seen with H89 (Fig.
5A), whereas the Rp-8-Br-cAMPS had no effect (Fig. 5A).
FIG. 1. Inhibition of PKA attenuates HCV infection. (A) Huh-7.5 cells were incubated with Ro-31-8220 (1 %M) (PKC inhibitor), H89 (10 %M)
(PKA inhibitor), PD98059 (10 %M) (MEK1 inhibitor), U0126 (10 %M) (MEK1/2 inhibitor), or SB203580 (10 %M) (p38MEK inhibitor) for 1 h and
infected with JFH-1 for 1 h in the presence of inhibitors. (B) Dose-dependent reduction of HCV infection by H89 inhibition of PKA. Huh-7.5 cells
were incubated for 1 h with increasing concentrations of H89 and infected with J6/JFH (!) or JFH-1 (‚). (C) Dose-dependent reduction of HCV
infection by myrPKI inhibition of PKA. Huh-7.5 cells were incubated for 1 h with increasing concentrations of myrPKI and infected with J6/JFH
(!) or JFH-1 (‚). Infectivity is expressed relative to untreated control cells and represents the mean of three replicate infections. The data
presented are from a single experiment and are representative of three independent experiments.
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Neither of the PKA-specific inhibitors had an effect on CD81
localization. Attempts to visualize SR-BI in control or treated
cells with monoclonal and polyclonal antibodies specific for
SR-BI were unsuccessful, probably reflecting the low level of
SR-BI expression in Huh-7.5 cells. To investigate whether in-
hibiting PKA altered the localization of other TJ proteins,
control and H89-treated cells were stained for zonula occlu-
dens type 1 (ZO-1) and occludin expression. H89 had no effect
on ZO-1 or occludin localization in Huh-7.5 cells (Fig. 5B).
PKA can be targeted to sites of potential substrates by
AKAPs, allowing the coordination of multiple signal transduc-
tion pathways. AKAP-IS is a potent and selective antagonist of
PKAII (1, 100, 101). Huh-7.5 cells were transfected to express
GFP-tagged AKAP-IS or a scrambled control peptide, and
CLDN1 localization was assessed. Typical plasma membrane
localization of CLDN1 was observed in cells expressing the
scrambled peptide; however, CLDN1 demonstrated an intra-
cellular localization in AKAP-IS-expressing cells (Fig. 5C).
CD81 expression and localization were unaltered in AKAP-IS- or
scrambled control peptide-expressing cells (data not shown).
These data lend further support for a role of PKAII in CLDN1
localization and HCV entry.
Imaging techniques that take advantage of FRET between
fluorescent proteins have been developed to study their asso-
ciation. We recently demonstrated FRET between DsRed-
CLDN1 (r.CLDN1) and AcGFP-CD81 (g.CD81) at the plasma
membrane, consistent with a subpopulation of molecules forming
a coreceptor complex (43). To elucidate a role of PKA in the
CLDN1 association with CD81, Huh-7.5 cells expressing g.CD81
(donor) and r.CLDN1 (acceptor) were treated with H89 or FK,
and the frequency of proteins in close enough proximity ((10
nm) for FRET to occur was assessed (percent FRET). H89 sig-
nificantly reduced the frequency of FRET between CD81 and
CLDN1 (FRET of 50.0% for control cells and 20.8% for H89-
treated cells [P ( 0.05 by Fisher’s exact test]), whereas FK treat-
ment had no significant effect (35.0% [not significant]). These
data suggest that the PKA-dependent localization of CLDN1 at
the plasma membrane is important for CLDN1 association with
CD81.
PKA-dependent infectivity of extracellular HCV. In hepato-
cytes, cAMP/PKA activity was previously reported to be im-
portant for the trafficking of lipids and apical plasma mem-
brane proteins (97, 100, 102, 106). We were interested to
determine whether PKA has a role in the secretion and infec-
tivity of extracellular HCV. J6/JFH- and JFH-1-infected cells
()80% NS5A!) were treated with increasing concentrations
of H89 for 1 h, the cells were washed extensively to remove
inhibitor, and the amount of infectious virus released from
control or treated cells was assessed. J6/JFH- and JFH-1-in-
fected Huh-7.5 cells released 1.7 $ 104 and 6.8 $ 104 IU/ml,
respectively. H89 treatment reduced the titer of infectious ex-
tracellular virus, with the highest dose (30 %M) reducing the
infectivities of J6/JFH and JFH-1 by 90% and 75%, respec-
tively (Fig. 6A). In contrast, H89 had no effect on the infec-
tivity of intracellular virus (Fig. 6B). The effects of H89 were
previously reported to be reversible (13), and we found that an
8-h “recovery period” following H89 treatment was sufficient
to restore extracellular virus infectivity to levels observed in the
untreated cultures (data not shown). Incubation of Huh-7.5
cells with myrPKI induced a dose-dependent decrease in ex-
FIG. 2. PKA-dependent HCV entry. (A) Dose-dependent reduction
of HCVpp entry by H89 inhibition of PKA. Huh-7.5 cells were incubated
for 1 h with increasing concentrations of H89 and infected with HCVpp-
JFH-1 (white bars) or MLVpp (black bars). (B) Dose-dependent reduc-
tion of HCVpp entry by myrPKI inhibition of PKA. Huh-7.5 cells were
incubated for 1 h with increasing concentrations of myrPKI and infected
with HCVpp-H77 (white bars) or MLVpp (black bars). (C) Huh-7.5,
Hep3B, Huh-7, 293T-CLDN1, and primary human hepatocytes (PHH)
were incubated with H89 (10 %M) for 1 h and infected with HCVpp-H77.
HCVpp-JFH-1 infection was assessed by flow cytometry, while for
HCVpp-H77 infection, the cells were lysed, and the mean luciferase
activity (relative light units) was measured; for all samples, the average
Env#pp value was subtracted. Infectivity is expressed relative to those of
untreated control cells and represents the mean of data from three rep-
licate infections. The data presented are from a single experiment and are
representative of three independent experiments.
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tracellular J6/JFH and JFH-1 virus infectivity by 62% and 80%,
respectively, at the highest dose (100 %M), confirming a spe-
cific role for PKA.
To further corroborate PKA specificity and to determine
which isoform modulates virus infectivity, infected cells were
incubated for 1 h with Rp-cAMPS or Rp-8-Br-cAMPS, and
cell-free virus infectivity was measured. Rp-cAMPS inhibited
the level of infectious JFH-1 and J6/JFH cell-free virus,
whereas Rp-8-Br-cAMPS did not, suggesting that PKAII mod-
ulates extracellular virus infectivity (Fig. 6D). To investigate
whether FK stimulation of PKA modulates the infectivity of
cell-free virus, infected cells were incubated with FK (10 %M)
for 1 h, the inhibitor was removed, and the infectivity of cell-
free virus was assessed. FK treatment increased the level of
infectious J6/JFH and JFH-1 cell-free virus, and this effect
could be inhibited by H89 (10 %M), demonstrating PKA
dependency (Fig. 6E).
To determine whether H89 affects the release of virus par-
ticles or their infectivity, we measured viral RNA in the cell-
free medium from control and treated cells (25, 28). The treat-
ment of infected cells with H89 for 1 h or 24 h had no
significant effect on the levels of cell-free viral RNA secreted
from cells or on the intracellular levels of HCV RNA (Fig. 7A
and B). Since the cAMP/PKA pathway has been implicated in
the regulation of exocytosis in secretory cells (69, 90, 102), we
investigated whether H89 treatment modulates Huh-7.5 secre-
tion of albumin. The level(s) of albumin released from naı¨ve or
HCV-infected cells was similar and not altered by H89 or FK
treatments (Fig. 7C), suggesting that the general secretory
pathway was not affected. These data demonstrate that inhib-
iting PKA activity decreases the infectivity of extracellular vi-
rus without inhibiting viral RNA replication or virus particle
release, suggesting a PKA-dependent step in the infectivity or
maturation of HCV particles.
Stability of extracellular HCV infectivity. We noted that
extracellular J6/JFH and JFH-1 infectivity declined over time
at 37°C (Fig. 8A); this loss in infectivity was not associated with
a decline in HCV RNA levels (Fig. 8B). To investigate whether
FIG. 3. Putative role for PKAII in HCV infection. (A) Huh-7.5 cells were incubated with the cAMP analogs Rp-cAMPS (500 %M) or
Rp-8-Br-cAMPS (500 %M) and infected for 1 h with J6/JFH (white bars) or JFH-1 (black bars). HCVcc-infected cells were fixed after 48 h and
stained for NS5A, and the mean number of infected cells per well was determined by flow cytometry. Infectivity is expressed relative to untreated
control cells and represents the mean of data from three replicate infections. The data presented are from a single experiment and are
representative of three independent experiments. (B) Huh-7.5 cells expressing PKAI& (white bars) or PKAII& (black bars) sensors were
preincubated with Rp-cAMPS (500 %M) or Rp-8-Br-cAMPS (500 %M) for 1 h, followed by FK/IBMX (50 %M and 500 %M, respectively)
stimulation for 30 min. The BRET signal was quantified using a Fusion& FP microplate reader, and data are plotted relative to untreated control
cells. The data were compiled from three independent experiments. (C) Huh-7.5 cells expressing PKAI& (white bars) or PKAII& (black bars)
sensors were preincubated with Rp-cAMPS (500 %M) or Rp-8-Br-cAMPS (500 %M) for 1 h, followed by FK (10 %M) stimulation for 30 min. The
data presented are compiled from three independent experiments. Statistical analysis using a Newman-Keuls multiple-comparison test confirms
that FK treatment significantly reduced the BRET signal compared to those of control untreated cells (P ( 0.05), while pretreatment with
Rp-cAMPS had no significant effect on the BRET signal relative to the control. Preincubation of cells with Rp-8-Br-cAMPS did not inhibit the
FK-stimulated decrease in BRET signal compared to the control.
FIG. 4. FK activation of PKA enhances HCV infection. Huh-7.5
cells were incubated with FK (10 %M) (PKA activator) for 1 h with or
without a 1-h preincubation with H89 (10 %M) (PKA inhibitor). Cells
were infected with J6/JFH (white bars) or JFH-1 (black bars) (A) and
HCVpp-JFH (B) for 1 h in the presence of PKA modulators. HCVcc-
infected cells were fixed after 48 h and stained for NS5A, and the mean
number of infected cells per well was determined by flow cytometry.
For HCVpp, the cells were lysed, the mean luciferase activity (relative
light units) was measured, and the average Env#pp value was sub-
tracted. Infectivity is expressed relative to untreated control cells and
represents the mean of data for three replicate infections. The data
presented are from a single experiment and are representative of three
independent experiments.
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PKA modulates the stability of extracellular virus infectivity,
JFH-1-infected cells were treated with H89 for 1 h, and the
extracellular virus was harvested during the first hour following
H89 removal and incubated at 37°C for 1 and 8 h. Virus
released from control or H89-treated cells showed a similar
loss of infectivity at 37°C over time, suggesting that PKA does
not alter or modulate the temperature-dependent properties
of extracellular virus infectivity (Fig. 8C).
Role of PKA in ApoB and ApoE secretion and buoyant
density of cell-free HCV particles. HCV replicates in cytoplas-
mic membrane vesicles, which are enriched with ApoB, ApoE,
and microsomal triglyceride transfer protein (MTP), proteins
known to be required for the assembly of very-low-density
lipoprotein (VLDL) (50). Recent reports demonstrated that
the treatment of hepatoma cells with an MTP inhibitor and
small interfering RNA silencing of ApoB and ApoE expression
reduced the levels of VLDL and HCV in the extracellular
medium, suggesting that viral secretion is dependent on VLDL
assembly and/or release (19, 38, 50). To ascertain whether H89
treatment of Huh-7.5 cells alters lipoprotein secretion, we
quantified ApoB and ApoE levels released from control and
treated cells. H89 reduced ApoB secretion from naı¨ve (data
not shown) and HCV-infected cells but had a negligible effect
on ApoE levels (Fig. 9A).
Extracellular HCVcc particles have been reported to have a
heterogeneous range of buoyant densities, with the lower-den-
sity forms representing VLDL-associated particles (38, 64, 78).
To assess whether the effects of H89 on ApoB secretion and
viral infectivity reflect an altered association of particles with
lipoproteins and the concomitant change in particle buoyant
density, we utilized iodixanol gradients to determine the buoy-
ant density of cell-free virus (63, 64, 78). Virus-containing
FIG. 5. Inhibition of PKA disrupts CLDN1 localization in Huh-7.5 cells. (A) Huh-7.5 cells were seeded onto glass coverslips and incubated with
dimethyl sulfoxide (DMSO) (control), H89 (10 %M), FK (10 %M), Rp-cAMPS (500 %M), or Rp-8-Br-cAMPS (500 %M). Cells were fixed and
stained for CLDN1 or CD81. (B) Huh-7.5 cells were incubated with DMSO (control) or H89 (10 %M) for 1 h, fixed, and stained for the TJ proteins
ZO-1 and occludin. Bound antibodies were visualized using Alexa Fluor 488 anti-mouse Ig. (C) Huh-7.5 cells were transduced to express
GFP-AKAP-IS or GFP-Scrambled peptide (green) and stained for CLDN1. Bound antibodies were visualized using Alexa Fluor 633 anti-mouse
antibodies (red). Nuclei were visualized using DAPI (blue). Laser scanning confocal microscopic images of single 1-%m z sections were obtained
using a 63$ 1.2-numerical-aperture objective (scale bar represents 10 %m).
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supernatant from control and H89-treated cells was analyzed
on an iodixanol gradient, and the density of HCV RNA-con-
taining fractions was determined. The distributions of particle
densities from control (Fig. 9B) or H89-treated cells (Fig. 9C)
were comparable. HCV exhibited a bimodal distribution of
buoyant density with peaks of HCV RNA at 1.155 and 1.087
g/ml for the control and at 1.152 and 1.086 g/ml for virus from
H89-treated cells. This is consistent with data from previous
reports (63, 64, 78) and suggests that the reduced infectivity is
not due to an altered particle buoyant density.
FIG. 6. PKA-dependent infectivity of extracellular HCV. (A) Dose-dependent reduction in extracellular HCV infectivity by H89. J6/JFH (!)-
and JFH-1 (‚)-infected Huh-7.5 cells were seeded in 48-well plates and incubated with increasing concentrations of H89 the following day. Cells
were extensively washed, supernatant was collected after 1 h, and infectivity was quantified. (B) J6/JFH-infected cells were incubated with H89 (10
%M) for 1 h (white bars) or 8 h (gray bars), the intracellular virus was released by repeated freeze-thaw cycles, and infectivity was quantified.
(C) Dose-dependent reduction in extracellular HCV infectivity by myrPKI. J6/JFH (!)- and JFH-1 (‚)-infected Huh-7.5 cells were seeded in
48-well plates and incubated with increasing concentrations of myrPKI the following day. Cells were extensively washed, supernatant was collected
after 1 h, and infectivity was quantified. (D) The infectivity of extracellular virus obtained from J6/JFH (white bars)- and JFH-1 (black
bars)-infected Huh-7.5 cells incubated with the isoform-specific PKA inhibitors Rp-cAMPS (500 %M) or Rp-8-Br-cAMPS (500 %M) for 1 h was
measured. (E) The infectivity of extracellular virus from J6/JFH (white bars)- and JFH-1 (black bars)-infected Huh-7.5 cells incubated for 1 h with
FK (10 %M) (PKA activator) in the presence and absence of H89 pretreatment (10 %M). Virus infectivity was determined by infection of naı¨ve
Huh-7.5 cells, and NS5A-positive cells were enumerated. Infectivity is expressed relative to control untreated cells and represents the mean of three
replicate infections. The data presented are from a single experiment and are representative of three independent experiments.
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HCV infection promotes cAMP levels and PKA activity.
Given the effects of H89 and FK on HCV entry and extracel-
lular virus infectivity, we were interested to investigate whether
infection modulates cAMP levels and PKA activity. Increased
cAMP levels were detected in J6/JFH- and JFH-1-infected
Huh-7.5 cells 72 h postinfection ()80% NS5A!) compared to
naı¨ve cells (Fig. 10A). As a control, naı¨ve Huh-7.5 cells were
shown to be highly responsive to FK treatment, demonstrating
a 78-fold increase in cAMP levels (Fig. 10A). Incubation of
Huh-7.5 cells with HCVcc virus or E1E2 glycoproteins for 1 h
had no detectable effect on cAMP levels (data not shown).
To assess whether the elevated cAMP levels observed in
HCV-infected cells activates PKA, we measured the reactivity
of an antibody specific for the phosphorylated PKA substrate
consensus motif (p-PKAs) with protein lysates from naı¨ve and
HCV-infected cells 72 h following infection (17, 61, 79). As
FIG. 7. Inhibition of PKA does not affect extracellular or intracel-
lular HCV RNA. Extracellular (A) and intracellular (B) HCV RNA
levels were quantified in control and H89 (10 %M)-treated JFH-1-
infected Huh-7.5 cells. Cells were incubated with H89 for 1 h (white
bars) or 24 h (black bars). HCV RNA was detected by RT-PCR and
quantified relative to a GAPDH control. (C) Effect of H89 on Huh-7.5
secretion of albumin. Huh-7.5 cells were treated with a DMSO control
or H89 (10 %M) for 1 h, and the levels of albumin in the extracellular
medium were quantified by ELISA. Data are expressed relative to
those for control untreated cells and represent values from the means
of three replicate infections. The data presented are from a single
experiment and are representative of two independent experiments.
FIG. 8. PKA does not regulate the stability of infectious extracellular virus. (A) The infectivities of extracellular J6/JFH (!) and JFH-1 (‚)
were assessed after incubation of the virus at 37°C for 0, 1, 2, 4, 8, and 24 h. (B) The HCV RNA content of extracellular J6/JFH was measured
preincubation (white bars) and postincubation (black bars) of virus at 37°C for 24 h. HCV RNA was detected by RT-PCR and quantified relative
to a GAPDH control. (C) Effect of H89 on the stability of extracellular JFH-1 infectivity. Extracellular virus was collected from control and H89
(10 %M)-treated JFH-1-infected Huh-7.5 cells and incubated at 37°C for 0 h (white bars), 1 h (gray bars), or 8 h (black bars), and infectivity was
assessed. Data are expressed as relative infectivity compared to control untreated cells and represent the means of data from three replicate
infections. The data presented are from a single experiment and are representative of two independent experiments.
FIG. 9. Effects of PKA modulators on ApoB and ApoE secretion and
HCV particle buoyant density. (A) Extracellular medium was collected from
control and H89 (10 %M)-treated Huh-7.5 cells, and the levels of ApoB
(white bars) and ApoE (black bars) were measured by capture ELISA. Data
are expressed relative to those for control untreated cells and represent the
mean of data for three replicate infections. The buoyant density (F) of
extracellular J6/JFH released from control (B) or H89-treated (C) Huh-7.5
cells was determined on iodixanol gradients. Individual bars show relative
HCVRNA copy numbers in each fraction compared to the maximum peak.
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expected, FK stimulation led to an increase in the number and
intensity of bands representing phosphorylated PKA substrates
compared to those of untreated cells (Fig. 10B). JFH-1 infec-
tion also increased the intensity and number of phosphorylated
PKA substrates compared to those of uninfected cells (Fig.
10B). The molecular masses of PKA substrates observed in
FK-treated and JFH-1-infected Huh-7.5 cells were compara-
ble; however, a 22-kDa band corresponding to the molecular
mass of CLDN1 was not detectable. To investigate whether
CLDN1 is a direct substrate for PKA, CLDN1 and PKA sub-
strates were immunoprecipitated from naı¨ve and JFH-1-in-
fected Huh-7.5 cell lysates, and the proteins were separated by
FIG. 10. HCV infection increases cAMP levels and PKA activity. (A) cAMP levels were measured in uninfected and J6/JFH- and JFH-1-
infected Huh-7.5 cells 72 h postinfection. As a control, Huh-7.5 cells were incubated with FK (10 %M), a compound known to activate adenylyl
cyclase and increase cAMP levels. cAMP levels are shown relative to control untreated cells and represent data from the means of three replicate
wells. (B) PKA activity was assessed by measuring the reactivity of an anti-PKA substrate-specific antibody (p-PKAs) with 10 %g of total protein
separated by SDS-PAGE from control (lane 1), FK (10 %M)-stimulated (lane 2), and JFH-1-infected (72 h postinfection) (lane 3) Huh-7.5 cells.
(C) CLDN1 and PKA substrates were immunoprecipitated from 100 %g of uninfected (UF) and JFH-1-infected (72 h postinfection) Huh-7.5 cell
lysates with specific antibodies (mouse anti-CLDN1, rabbit anti-CLDN1, and p-PKAs) and control antibodies (murine IgG [mIgG] and rabbit Ig
[rIgG]). Immunoprecipitates were subjected to SDS-PAGE, and reactivity with rabbit anti-CLDN1 was assessed by Western blotting. (D and E)
Uninfected (D) and JFH-1-infected (E) (72 h postinfection) Huh-7.5 cells were incubated with FK or H89 for 1 h (H89 ) FK indicates a 1-h
preincubation with H89 prior to FK treatment), fixed, and stained with the PKA substrate-specific antibody (p-PKAs) (green). JFH-1-infected cells
were visualized by staining for NS5A (red), and nuclei were counterstained with DAPI (blue). Laser scanning confocal microscopic images of single
1-%m z sections were obtained using a 63$ 1.2-numerical-aperture objective (scale bar represents 10 %m).
8806 FARQUHAR ET AL. J. VIROL.
 at UNIV OF BIRM
INGHAM
 on M
ay 14, 2009 
jvi.asm
.org
Downloaded from
 
SDS-PAGE and tested for reactivity with antibodies specific
for CLDN1 and PKA substrate. Anti-CLDN1 antibodies
readily precipitated CLDN1 from cell lysates; however, these
proteins were not recognized by p-PKAs (Fig. 10C). We ob-
served no evidence of CLDN1 phosphorylation by PKA in
Huh-7.5 cells incubated for 1 h with either HCVcc or E1E2
(data not shown).
To study PKA activity at the cellular level, naı¨ve and JFH-
1-infected Huh-7.5 cells were incubated with FK (10 %M) or
H89 (10 %M) for 1 h, fixed, and stained with p-PKAs and
NS5A-specific Abs. FK-treated naı¨ve cells demonstrated in-
creased cytoplasmic staining with p-PKAs that was abrogated
by prior treatment with H89, indicating a cytoplasmic localiza-
tion of PKA substrates (Fig. 10D). JFH-1-infected cells dis-
played increased cytoplasmic staining with p-PKAs compared
to uninfected cells, which was abrogated by treatment with H89
(Fig. 10E), while FK did not increase p-PKA cytoplasmic stain-
ing in infected cells. The intracellular PKA substrate staining
did not colocalize with anti-CLDN1 (data not shown), further
suggesting that CLDN1 is not a direct substrate for PKA. In
summary, these data show that HCV infection of Huh-7.5 cells
leads to an increase in cAMP levels, which in turn activates
PKA to phosphorylate various cellular targets, which may pro-
mote the infectivity of extracellular virus and increase viral
transmission within the culture.
DISCUSSION
Protein kinases have been implicated in the life cycle of
many viruses including adenovirus, herpes simplex virus, and
influenza virus (91, 93, 103). By screening a series of kinase
inhibitors for their effect(s) on HCV infection, we identified
PKA as having an important role both in HCV entry and in the
genesis of infectious extracellular virus.
Treatment of Huh-7.5 cells with the general PKA-C inhibi-
tor H89, the specific PKA-C inhibitor myrPKI, and cAMP
antagonist Rp-cAMPS inhibited HCVcc and HCVpp infection
(Fig. 1 to 3), demonstrating that HCV internalization is de-
pendent on the target cell expression of active PKA. A similar
level of inhibition of HCVpp entry was noted for other cell
types, including primary human hepatocytes, demonstrating
the generality of this observation. Since HCV entry is depen-
dent on the host cell expression of CD81, SR-BI, and CLDN1,
we investigated whether inhibition of PKA altered viral recep-
tor expression and localization. H89 or Rp-cAMPS had no
effect on total coreceptor expression levels when quantified by
flow cytometry or Western blotting. However, confocal imag-
ing of treated cells identified intracellular forms of CLDN1
with reduced levels of expression at the plasma membrane
(Fig. 5A). CD81 localization was unchanged in H89-, Rp-
cAMPS-, or FK-treated cells (Fig. 5A). There was no discern-
ible effect of FK treatment on CLDN1 localization (Fig. 5A),
consistent with the negligible effect on HCVpp infection.
These data support a model where CLDN1 localization at the
plasma membrane is dependent on PKA and is essential for
viral receptor activity.
We (43) and others (104) previously reported that CLDN1
associates with CD81 at the plasma membrane of Huh-7 cells,
suggesting that coreceptor complexes have a role to play in the
viral entry process. The observation that H89 treatment re-
duced FRET between CLDN1 and CD81 lends further sup-
port for a PKA-dependent localization of CLDN1 at the
plasma membrane.
The cellular localization of several members of the CLDN
family is reported to be regulated by growth factors (92) and
kinases: CLDN1 by MAPK (37), CLDN3 by PKA (31),
CLDN4 by EphA2 (94) and PKC (32), and CLDN16 by PKA
(51). The functional consequences of CLDN phosphorylation
are specific for certain CLDN family members and are most
likely dependent upon the cell type under study. CLDN1 con-
tains several potential PKA phosphorylation sites located at
amino acids S34 and S69 in the first extracellular loop, S173 in
the first transmembrane domain, and T190 in the C-terminal
cytoplasmic region. Evans and colleagues previously reported
that amino acids I32 and E48 within extracellular loop 1 of
CLDN1 are critical for coreceptor activity (34), with I32 form-
ing part of the PKA phosphorylation consensus site. During
the dynamic remodeling of tight junctions, claudins have been
reported to internalize (70); indeed, we have observed intra-
cellular forms of CLDN1 in Huh-7.5 cells (M. J. Farquhar,
unpublished observations). Consequently, it is feasible that
residues within the extracellular loops may be targets for PKA
phosphorylation. The entire C-terminal CLDN1 tail is not re-
quired for HCV coreceptor activity in 293T embryonal kidney
cells (34, 43), suggesting that this region is not the site for PKA
phosphorylation. This is in contrast to recent reports demon-
strating the importance of CLDN3 and CLDN16 C-terminal
cytoplasmic tails in PKA phosphorylation (31, 51). However,
we were unable to demonstrate CLDN1 recognition by a PKA
substrate-specific antibody (Fig. 10B and C), suggesting that
CLDN1 is not directly phosphorylated by PKA. It should be
noted that CLDN1 is an integral membrane protein that asso-
ciates with other intercellular junctional and associated cyto-
solic proteins that may be modulated by PKA (5, 57, 58).
PKA plays an important role in the regulation of protein
trafficking along the constitutive secretory pathway and has
been implicated in protein transport from the endoplasmic
reticulum to the Golgi apparatus and from the Golgi apparatus
and trans-Golgi network to the plasma membrane (18, 75).
More recently, PKA has been reported to have a fundamental
role in the polarized trafficking of apical proteins and lipids in
the development of hepatic canalicular structures (52, 86, 98).
H89, myrPKI, and Rp-cAMPS inhibition of PKA in HCV-
infected Huh-7.5 cells reduced the infectivity of extracellular
virus without modulating the level(s) of infectious virus or
HCV RNA within the cell (Fig. 6B and 7B). H89 did not alter
the amount of HCV RNA released from cells, suggesting that
particle release is not affected. This is consistent with the
observation that H89 treatment did not affect albumin secre-
tion (Fig. 7C), suggesting that the general secretory pathway of
the cells was not perturbed. Interestingly, FK treatment of
HCV-infected cells in order to activate PKA (Fig. 10A) in-
creased the infectivity of extracellular virus (Fig. 6E), suggest-
ing that basal levels of PKA activity may limit extracellular
virus infectivity.
To address how PKA modulates extracellular virus infectiv-
ity, it is important to consider the processes underlying HCV
particle assembly and release. Recent data have highlighted
the critical role of lipoprotein assembly and secretion in the
HCV life cycle. The HCV core protein is an essential compo-
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nent of particles, and association with lipid droplets is critical
for the genesis of infectious particles (16, 74). Furthermore,
the efficient release of particles from infected cells is reported
to be dependent on VLDL assembly and secretion (19, 38, 50).
The inhibition of PKA in naı¨ve and HCV-infected Huh-7.5
cells reduced ApoB secretion by approximately 50% but had
no effect on ApoE levels (Fig. 9A). However, the buoyant
densities of particles released from H89-treated cells were
comparable to those from untreated cells, suggesting that
HCV particle association with lipoproteins is not regulated by
PKA (Fig. 9B and C). This conclusion is further supported by
the negligible effect(s) of PKA inhibitors on extracellular HCV
RNA levels (Fig. 7A), in contrast to the previously reported
inhibitory effect(s) of MTP inhibitors on both VLDL and HCV
particle secretion (19, 38, 50).
In mammalian cells, PKA exists as two major isoforms, type
I and type II, where PKAI localizes predominately in the cy-
toplasm and PKAII associates with cellular structures and or-
ganelles via AKAPs (89). Rp-cAMPS demonstrated a specific
inhibition of HCV entry and infectious extracellular virus,
whereas Rp-8-Br-cAMPS had no effect (Fig. 3A and 6D). To
aid the interpretation of these results, we studied the PKA
isoform specificity of the Rp analogs in Huh-7.5 cells using a
recently developed BRET assay (29). Rp-8-Br-cAMPS specif-
ically inhibited FK/IBMX-stimulated PKAI and not PKAII
(Fig. 3B), suggesting a minimal involvement of PKAI in HCV
infection.
FK treatment of Huh-7.5 cells stimulates PKAII but not
PKAI (Fig. 3C), which may be attributable to their different
subcellular locations. FK activates adenylyl cyclases at the
plasma membrane and, in the absence of IBMX, PDEs will
degrade cAMP before it reaches the intracellularly located
PKAI. Rp-cAMPS had no effect on FK/IBMX-stimulated
PKAII (Fig. 3B). However, treating cells with FK alone al-
lowed us to demonstrate the specific inhibition of PKAII by
Rp-cAMPS (Fig. 3C) and to confirm a role for PKAII in HCV
infection.
PKAII is known to regulate diverse cellular functions due to
its localization via AKAPs (22, 23, 100). GFP-AKAP-IS ex-
pression in Huh-7.5 cells was unstable, and we were unable to
study HCV infection and viral protein trafficking in the trans-
dominant-negative expressing cells. However, transient expres-
sion of AKAP-IS peptide, a specific AKAP disruptor of PKAII,
in Huh-7.5 cells led to a relocalization of CLDN1 (Fig. 5C),
confirming that PKA regulates CLDN1 targeting to the plasma
membrane in an AKAP-dependent manner. Overall, our stud-
ies suggest a specific role for the PKAII isoform in the entry
and infectivity of cell-free particles.
PKAII-AKAP interactions at the Golgi-centrosomal area
(12, 101, 102) may coordinate lipid, cellular, and viral protein
trafficking in Huh-7.5 cells. Thus, it is conceivable that inhibi-
tion of PKA may alter the passage of virus through the Golgi
apparatus, resulting in the attenuation of its infectivity. HCV
glycoproteins in the endoplasmic reticulum comprise high-
mannose sugars, which are trimmed during their transit from
the endoplasmic reticulum to the Golgi apparatus to complex
type sugars (40). Experiments to determine the molecular
weight and endoglycosidase sensitivity of extracellular particle-
associated GPs yielded inconclusive data due to low viral
yields. Helle and colleagues (45) reported that the neutralizing
activity of anti-HCV antibodies was modulated by specific E2
glycans. Interestingly, cell-free virus released from control or
H89-treated cells demonstrated sensitivities comparable to
those obtained with neutralization by GP-specific monoclonal
antibodies and patient IgG (data not shown), suggesting no
major alteration(s) in the glycosylation status of particle-asso-
ciated GPs released from treated cells.
We noted increased levels of cAMP and PKA substrates in
infected cells (Fig. 10), supporting a model where HCV infec-
tion activates PKA in a cAMP-dependent manner as a mech-
anism to promote the infectivity of cell-free virus and viral
transmission. Our evidence using HCVcc is in contrast to pre-
vious reports where the activity of PKA-C was inhibited with
peptides corresponding to a sequence within the HCV NS3
region and recombinant NS3/NS4A (4, 15). Several examples
exist, however, where viruses activate cAMP/PKA pathways,
adenovirus activates PKA to enhance nuclear targeting via the
microtubule network (94), and HIV infection is associated with
increased levels of intracellular cAMP and constitutive PKA
activation that are required for efficient proviral DNA synthe-
sis (2, 47). Kim and colleagues reported that NS2 activated
cAMP-dependent pathways in Huh-7 cells, supporting JFH-1
subgenomic replicons (55). Our data imaging PKA substrates
in HCV-infected cells demonstrate colocalization with NS5A,
suggesting that NS5A or other components of the viral repli-
case complex may be substrates for PKA (Fig. 10E). Experi-
ments to investigate whether HCV particle interactions with
cell surface receptors promote cAMP levels were inconclusive
and may reflect low viral titers that fail to saturate cell surface-
expressed receptors. Alternatively, the virus may induce
cAMP-independent activation of PKA by second messenger
lipids such as sphingosine (68) or via cross talk between sig-
naling pathways. In addition, there may be endogenous PKA
activity within the particle, as reported previously for hepatitis
B virus, which encapsidates PKC into its core particle (53). In
summary, we demonstrate a role for PKAII both in the infec-
tivity of extracellular virus and in viral entry, highlighting po-
tential new targets for therapy.
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